Saturday, 25 May 2024

Australia's most trusted
source of pharma news

Saturday, 25 May 2024
Listen to this story 

Pharma to cut 50% of staff

Posted 17 April 2024 AM

ASX-listed Imugene is reducing its headcount by 50 per cent with the sale of its North Carolina cell therapy manufacturing facility to Kincell Bio for up to US$6 million [AUD$9.3 million].

As a result of the transfer, which includes an upfront payment plus milestone-driven payments over the next three years, Imugene will realise US$32 million [AUD$49.9 million] in staff cost reductions, manufacturing efficiencies and overhead savings over the period.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (20)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (6)

Other (32)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.